Literature DB >> 1341321

Bone marrow cells in the DNA-synthesis-phase in the myelodysplastic syndrome and lymphome.

A M Wenthzel1, A Porwit, K Lindahl, S Widell, P Reizenstein.   

Abstract

The bromodeoxyuridine (BRDU) labelling of bone marrow cells was studied in 46 subjects. The labelling in 14 patients, mostly untreated, with the myelodysplastic syndrome (MDS) and four lymphoma patients was significantly (p = 0.043) higher (11.38 +/- SE 2.3% S-phase cells) than that of marrow cells (7.18 +/- SE 1.04%) from 14 apparently healthy normal controls and from nine patients with non hematologic disease. Six iron deficiency had numerically but not significantly increased values. Bone marrow samples from MDS-patients showing the highest numbers of cells in the DNA-synthesis phase had the lowest numbers of colonies and clusters in the CFU-C assay (p < 0.03). The data suggest that the DNA-synthesis period is longer in MDS than in controls.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1341321     DOI: 10.1007/bf02989654

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  17 in total

1.  Characterization of clonogenic cells in refractory anemia with excess of blasts (RAEB-CFU): response to recombinant hematopoietic growth factors and maturation phenotypes.

Authors:  H C Schouten; R Delwel; F J Bot; A Hagemeijer; I P Touw; B Löwenberg
Journal:  Leuk Res       Date:  1989       Impact factor: 3.156

2.  Percentage of S-phase cells in bone marrow aspirates, biopsy specimens and bone marrow aspirates corrected for blood dilution from patients with acute leukemia.

Authors:  L P Colly; W G Peters; J Hermans; W Arentsen-Honders; R Willemze
Journal:  Leuk Res       Date:  1987       Impact factor: 3.156

3.  In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.

Authors:  A Raza; K Ucar; H D Preisler; G Mayers
Journal:  Semin Oncol       Date:  1985-06       Impact factor: 4.929

4.  Double labeling of human leukemic cells using 3H-cytarabine and monoclonal antibody against bromodeoxyuridine.

Authors:  A Raza; H D Preisler
Journal:  Cancer Treat Rep       Date:  1985-02

5.  A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr.

Authors:  A Raza; Y Maheshwari; Z Yasin; N Mandava; G Mayers; H D Preisler
Journal:  Leuk Res       Date:  1987       Impact factor: 3.156

6.  Variation of proliferative activity in leukemic cell populations of patients with acute leukemia.

Authors:  E F Saunders; B C Lampkin; A M Mauer
Journal:  J Clin Invest       Date:  1967-08       Impact factor: 14.808

7.  Studies of cellular proliferation in human leukemia. I. Estimation of growth rates of leukemic and normal hematopoietic cells in two adults with acute leukemia given single injections of tritiated thymidine.

Authors:  B Clarkson; T Ohkita; K Ota; J Fried
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

8.  Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes.

Authors:  E Hellström; K H Robèrt; G Gahrton; H Mellstedt; C Lindemalm; S Einhorn; M Björkholm; G Grimfors; A M Udén; J Samuelsson
Journal:  Eur J Haematol       Date:  1988-05       Impact factor: 2.997

9.  Kinetic studies of cells in childhood leukemias.

Authors:  A M Mauer; S B Murphy
Journal:  Am J Clin Pathol       Date:  1979-10       Impact factor: 2.493

10.  Analysis of cell cycle characteristics and course of the disease in ANLL.

Authors:  A Raza; Y Maheshwari; W Brereton; H D Preisler
Journal:  Am J Hematol       Date:  1987-01       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.